

Result Update 13th August, 2025

Jyothy Labs Ltd.



Topline Stalls, Margins Slip; Downgrade to HOLD

Est. Vs. Actual for Q1FY26: Revenue - MISS; EBITDA - MISS; PAT - MISS

Changes in Estimates post Q1FY26

FY26E/FY27E: Revenue: -2%/-2%; EBITDA: -6%/-6%; PAT: -6%/-6%

Recommendation Rationale

- Muted revenue trajectory: Jyothy Labs reported Q1 revenue of Rs 751 Cr, up 1.3% YoY, supported by 3.6% volume growth (~5% volume growth excluding the HI segment). Rural demand remained steady, cushioning the effect of subdued urban consumption, where inflationary pressures and a shift toward convenience-led channels weighed on general trade. Modern trade, e-commerce, and quick commerce recorded double-digit growth. The value—volume gap was driven by higher grammage and promotional pricing in select categories. Fabric Care grew 3.3%, while Dishwash (+0.1%) and Personal Care (+0.7%) were broadly flat. Household Insecticides declined 9.7% YoY due to weak coil sales. Management expects the value—volume gap to persist in Q2, narrowing from Q3 as promotional intensity eases. Early signs of urban recovery emerged in July; however, the demand trajectory in the coming months remains a key monitorable.
- Margins Pressure: Jyothy Labs' gross margin contracted 326 bps YoY to 48%, impacted
 by elevated crude derivative costs and heightened competitive intensity in the dishwash
 segment. Selective price hikes provided partial relief. EBITDA margin stood at 16.5%, down
 146 bps YoY. Management maintained its guidance of sustaining historical EBITDA margins
 in the 16–17% range, anticipating a rebound in H2, supported by improved demand traction
 and a more benign cost environment.
- Demand Outlook: Jyothy Labs remains cautiously optimistic for H2FY26, with recovery
 momentum expected from Q3, supported by a normal monsoon, easing inflation, and
 festive-driven discretionary spending. New launches, sustained brand investments, and
 sharper route-to-market strategies are expected to enhance category relevance and
 accelerate growth. The company continues to focus on innovation, cost efficiency, and
 distribution expansion to drive profitable and sustainable growth amid evolving consumer
 behaviour.

Sector Outlook: Cautious

Company Outlook & Guidance: We have cut our EPS FY26/FY27 estimates to account for weak urban demand and have downgraded the stock from BUY to HOLD.

Current Valuation: 31x Mar-27 EPS (Earlier Valuation: 33x Mar-27 EPS).

Current TP: Rs 355/share (Earlier TP: Rs 400/share).

Recommendation: Considering the near-term challenges, we have downgraded the stock from BUY to HOLD and revised our TP to Rs 355/share, implying an upside potential of 7% from the CMP.

Financial Performance: Jyothy Labs reported muted results, with revenue growth of 1.3% YoY supported by a 3.6% YoY increase in volumes. Gross margins contracted by 326 bps YoY to 48% due to elevated input costs. EBITDA came in at Rs 124 Cr, down 7% YoY, with margins declining 146 bps YoY to 16.5%. Adjusted PAT stood at Rs 97 Cr, registering a ~5% YoY decline.

Key Financials (Consolidated)

(Rs Cr)	Q1FY26	QoQ (%)	YoY (%)	Axis Est.	Variance (%)
Net Sales	751	12.6	1.3	764	(1.7)
EBITDA	124	10.9	(7.0)	135	(7.9)
EBITDA Margin (%)	16.5	-26 bps	-146 bps	17.6	-111 bps
Net Profit	97	26.9	(4.8)	100	(3.7)
EPS (Rs)	2.6	26.9	(4.8)	2.7	(3.7)

Source: Company, Axis Research

(CMP as of 12	eth August, 2025)
CMP (Rs)	332
Upside /Downside (%)	7%
High/Low (Rs)	595/268
Market cap (Cr)	12,217
Avg. daily vol. (6m) Shrs'000.	732
No. of shares (Cr)	36

Shareholding (%)

	Dec-24	Mar-25	Jun-25
Promoter	62.9	62.9	62.9
FIIs	14.4	13.1	12.7
MFs / UTI	14.3	14.9	14.6
Banks / Fls	0.0	0.0	0.0
Others	8.5	9.1	9.9


Financial & Valuations

Y/E Mar (Rs Cr)	FY25	FY26E	FY27E
Net Sales	2,847	3,018	3,304
EBITDA	500	507	566
Net Profit	370	378	422
EPS (Rs)	10.2	10.3	11.5
PER (x)	33	32	29
EV/EBITDA (x)	23	23	20
P/BV (x)	6	5	5
ROE (%)	18.3	16.5	16.4

Change in Estimates (%)

Y/E Mar	FY26E	FY27E
Sales	-2%	-2%
EBITDA	-6%	-6%
PAT	-6%	-6%

Relative Performance



Source: Ace Equity, Axis Securities

SuhaneeShome

Research Associate suhanee.shome@axissecurities.in



Valuation & Outlook

We maintain a constructive long-term view on Jyothy Labs, supported by its consistent performance and strategic growth drivers—scaling value offerings via LUPs alongside premiumisation in Detergents and Dishwash, expanding into the broader Body Wash segment, and strengthening distribution through improved execution and channel partnerships. However, near-term headwinds remain, with weak urban demand, general trade underperformance amid a consumer shift toward e-commerce, quick commerce, and modern trade, as well as continued softness in the HI segment. Considering these challenges, we downgrade our rating from BUY to HOLD and revise our TP to Rs 355/share, implying an upside potential of 7% from the CMP.

Other Concal Key Highlights

A) Segmental Performance

Fabric Care: The category comprises Fabric Whitener, Fabric Enhancer, Bar Soap, Detergent Powder, and Liquid Detergent.

- The Fabric Care portfolio posted a steady 3.3% growth, driven by robust traction in liquid detergents, which more than doubled YoY and delivered strong sequential double-digit value growth. The company's multi-brand architecture—Henko, Ujala, Henkomatic, Mr. White, and Morelight—enabled effective segmentation across price tiers.
- The newly launched Ujala Young & Fresh fabric conditioner is gaining early acceptance, aided by targeted campaigns featuring Keerthy Suresh. Post-wash offerings, including Ujala Supreme and Ujala Crisp & Shine, continued to leverage celebrity-led ATL and sampling initiatives to expand category adoption. In detergents, focus remained on accelerating liquid adoption through on-ground activations, e-commerce-led sampling, and value-led positioning for Henko, Morelight, and Mr. White.
- While both Main Wash and Post Wash segments delivered mid-single-digit volume growth, competitive intensity remains
 elevated. Management is closely tracking pricing dynamics and adopting calibrated measures to protect margins while
 sustaining category leadership.

Dishwash: This category includes Dishwashing Bars (Exo), Liquids, Gels, Powders, and Scrubbers.

- The Dishwashing segment reported muted value growth of 0.1%, as healthy volumes, driven by mid-teen growth in Pril liquid
 and high single-digit gains in Exo bars, were offset by intensified price competition and higher grammage promotions.
- Pril sustained its double-digit momentum through competitive refill pack pricing and high-impact TV/digital campaigns featuring Genelia and Riteish, supported by trial-led initiatives. Exo strengthened its antibacterial positioning with celebrity-led ATL campaigns, low unit pack strategy, and on-ground activations, driving market share gains.
- While competitive intensity remains elevated, consistent brand investments and consumer stickiness underpin category resilience, positioning the segment for recovery in value terms once pricing pressures ease..

Personal Care: This category includes Body Soap, Hand Wash, and Toothpaste.

• The Personal Care segment posted a modest 0.7% revenue growth, with early signs of recovery supported by encouraging uptake of the newly launched 'Jovia' beauty soap and sustained traction in 'Margo Neem Naturals'. Strategic brand investments, including national multimedia campaigns featuring Raashii Khanna, promotional packs, and on-ground activations, have strengthened visibility and consumer recall. While recent price hikes in soaps exerted some volume pressure, intensified focus on portfolio expansion and brand equity positions the segment for improved performance ahead

Household Insecticides: This category includes Mosquito Repellent Coil and Liquid Vaporiser, Racquet and Aerosol.

- The Household Insecticides (HI) segment reported a 9.7% decline, led by continued weakness in mosquito coil sales, while the Liquid Vaporiser sub-category remained stable and now contributes ~50% of the HI portfolio, reflecting a clear shift in consumer preference.
- Strategic initiatives remain focused on rebalancing the portfolio toward higher-margin, newer formats such as Maxo Aerosols
 and Anti-Mosquito Racquets, supported by targeted campaigns featuring Kareena Kapoor and expanded distribution reach.
- While near-term performance is expected to remain muted, management aims to significantly reduce losses and turn the segment profitable by H2FY27 through portfolio premiumisation, category innovation, and capital-efficient execution.
- B) Distribution Channel: Jyothy Labs witnessed continued channel shift in Q1, with modern trade—including e-commerce and quick commerce—sustaining double-digit growth, supported by evolving consumer preferences and focused execution. Rural markets once again outperformed urban counterparts, reflecting inherent resilience, while general trade volumes remained under pressure. The shift is particularly pronounced in urban areas, where consumers increasingly prioritise convenience, driving traction for e-commerce and quick commerce platforms, even as some traditional outlets face declining sales or closures.



Key Risks to Our Estimates and TP

Prolonged recovery in urban/rural, raw material inflation, and an increase in the competitive intensity.

Change in Estimates

	Old Est.		Revised Est.		% Revision	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	3,075	3,382	3,018	3,304	-2%	-2%
EBITDA	537	604	507	566	-6%	-6%
PAT	401	451	378	422	-6%	-6%
EPS	10.9	12.2	10.3	11.5	-6%	-6%

Source: Company, Axis Securities

Results Review

(Rs Cr)	Q1FY25	Q4FY25	Axis Est.	Q1FY26	% Change (YoY)	% Change (QoQ)	Var (%) Axis Sec Est.
Net Sales	742	667	764	751	1.3	12.6	(1.7)
Gross Profit	380	328	383	361	(5.2)	10.0	(5.8)
Gross Margin (%)	51.3	49.2	50.1	48.0	-326 bps	-116 bps	-208 bps
Employee Expenses	86	78	90	87	0.6	10.8	(4.2)
Ad-spends	62	53	60	59	(4.4)	10.2	(2.4)
Other Expenses	99	84	97	91	(8.3)	7.8	(6.4)
EBITDA	133	112	135	124	(7.0)	10.9	(7.9)
EBITDA Margin (%)	18.0	16.8	17.6	16.5	-146 bps	-26 bps	-111 bps
Oth. Inc	14	15	16	19	41.7	25.6	19.6
Interest	1	2	2	1	(3.6)	(19.3)	(23.1)
Depreciation	13	15	15	15	9.8	1.2	(3.6)
EO Items	-	(4)	-	-			
PBT	132	111	134	128	(3.7)	14.7	(4.8)
Tax	31	31	33	31	0.2	0.3	(8.2)
Reported PAT	102	76	100	97	(4.8)	26.9	(3.7)
EPS	2.8	2.1	2.7	2.6	(4.8)	26.9	(3.7)

Source: Company, Axis Securities



Financials (Consolidated)

Profit & Loss (Rs Cr)

Y/E March	FY24	FY25	FY26E	FY27E
Net sales	2,755	2,847	3,018	3,304
Growth, %	10.9	3.3	6.0	9.5
Other operating income	2	-	-	-
Total income	2,757	2,847	3,018	3,304
Raw material expenses	(1,404)	(1,420)	(1,540)	(1,663)
Employee expenses	(301)	(326)	(339)	(380)
Other Operating Expenses	(572)	(602)	(632)	(695)
EBITDA (Core)	480	500	507	566
Growth, %	52.1	4.0	1.4	11.8
Margin, %	17.4	17.5	16.8	17.1
Depreciation	(50)	(56)	(61)	(65)
EBIT	431	443	446	501
Growth, %	62.1	2.9	0.5	12.5
Margin, %	15.6	15.6	14.8	15.2
Other Income	54	56	58	61
Non-recurring Items	-	(4)	-	-
Pre-tax profit	480	489	497	555
Tax provided	(110)	(118)	(119)	(133)
Net Profit	370	370	378	422
Growth, %	59.1	1.2	0.9	11.6

Source: Company, Axis Securities

Balance Sheet (Rs Cr)

Y/E March	FY24	FY25	FY26E	FY27E
Cash & bank	166	142	381	640
Debtors	201	274	291	319
Inventory	284	328	348	381
Loans & advances	264	163	163	163
Other current assets	33	47	47	47
Total current assets	1,139	1,411	1,687	2,006
Investments	-	-	-	-
Gross fixed assets	1,451	1,523	1,573	1,623
Less: Depreciation	(326)	(382)	(443)	(508)
Add: Capital WIP	13	22	22	22
Net fixed assets	1,139	1,164	1,153	1,138
Non-current assets	58	67	67	67
Total assets	2,401	2,691	2,955	3,260
Current liabilities	481	511	528	557
Provisions	80	91	91	91
Total current liabilities	561	601	619	648
Non-current liabilities	30	40	40	40
Total liabilities	591	641	659	688
Paid-up capital	37	37	37	37
Reserves & surplus	1,772	2,013	2,260	2,535
Shareholders' equity	1,810	2,050	2,296	2,572
Total equity & liabilities	2,401	2,691	2,955	3,260

Source: Company, Axis Securities



Cash Flow (Rs Cr)

Y/E March	FY24	FY25	FY26E	FY27E
Pre-tax profit	480	489	497	555
Depreciation	50	56	61	65
Chg in working capital	(201)	(16)	(19)	(31)
Total tax paid	(84)	(86)	(119)	(133)
Cash flow from operating activities	244	443	420	455
Capital expenditure	(56)	(81)	(50)	(50)
Chg in marketable securities	(192)	(265)	-	-
Cash flow from investing activities	(248)	(346)	(50)	(50)
Free cash flow	(4)	97	370	405
Equity raised/(repaid)	-	-	-	-
Dividend (incl. tax)	(129)	(129)	(131)	(146)
Cash flow from financing activities	(131)	(120)	(131)	(146)
Net chg in cash	(135)	(23)	239	259
Opening cash balance	283	166	142	381
Closing cash balance	166	142	381	640

Source: Company, Axis Securities


Ratio Analysis (%)

Y/E March	FY24	FY25	FY26E	FY27E
Per Share data				
EPS (INR)	10.0	10.2	10.3	11.5
Growth, %	58.6	1.2	0.9	11.6
Book NAV/share (INR)	49.1	55.6	62.3	69.8
FDEPS (INR)	10.0	10.2	10.3	11.5
CEPS (INR)	11.4	11.8	11.9	13.2
CFPS (INR)	5.0	10.8	9.8	10.7
DPS (INR)	3.5	3.5	3.6	4.0
Return ratios				
Return on assets (%)	16.8	14.8	13.6	13.8
Return on equity (%)	20.5	18.3	16.5	16.4
Return on capital employed (%)	21.0	18.4	16.7	16.7
Turnover ratios				
Asset turnover (x)	2.0	1.9	2.0	2.2
Sales/Total assets (x)	1.2	1.1	1.1	1.1
Sales/Net FA (x)	2.4	2.5	2.6	2.9
Working capital/Sales (x)	0.1	0.1	0.1	0.1
Receivable days	26.7	35.2	35.2	35.2
Inventory days	37.6	42.1	42.1	42.1
Payable days	44.3	45.1	44.7	44.9
Working capital days	39.9	38.7	38.8	38.9
Liquidity ratios				
Current ratio (x)	2.4	2.8	3.2	3.6
Quick ratio (x)	1.8	2.1	2.5	2.9
Valuation				
PER (x)	33.1	32.7	32.4	29.1
PEG (x) - y-o-y growth	0.6	27.2	37.6	2.5
Price/Book (x)	6.8	6.0	5.3	4.8
EV/Net sales (x)	4.3	4.1	3.8	3.4
EV/EBITDA (x)	24.9	23.5	22.7	19.8
EV/EBIT (x)	27.7	26.4	25.8	22.4

Source: Company, Axis Securities



Jyothy Labs Price Chart and Recommendation History



Date	Reco	TP	Research
01-Feb-24	BUY	565	Result Update
16-May-24	BUY	500	Result Update
26-Jul-24	BUY	524	Result Update
13-Nov-24	BUY	500	Result Update
01-Feb-25	BUY	450	Result Update
13-May-25	BUY	400	Result Update
13-Aug-25	HOLD	355	Result Update

Source: Axis Securities



Axis Securities Limited is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector banks and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.

Axis Securities Limited, is registered as a

- Stock Broker, Depository Participant, Portfolio Manager, Investment Adviser and Research Analyst with Securities and Exchange Board of India
- · Corporate Agent with Insurance Regulatory and Development Authority of India
- Point of Presence with Pension Fund Regulatory and Development Authority
- Distributor for Mutual Funds with AMFI

Registration Details:

SEBI Single Reg. No. - NSE, BSE, MSEI, MCX & NCDEX – INZ000161633 | SEBI Depository Participant Reg. No. IN-DP-403-2019 | Portfolio Manager Reg. No. - INP000000654 | Investment Advisor Reg No. INA000000615 | SEBI-Research Analyst Reg. No. INH000000297 | IRDA Corporate Agent (Composite) Reg. No. CA0073 | PFRDA – POP Reg. No. POP387122023 | Mutual Fund Distributor ARN- 64610.

Compliance Officer Details: Name - Mr. Rajiv Kejriwal, Tel No. - 022-68555574, Email id - compliance.officer@axisdirect.in.;

Registered Office Address - Axis Securities Limited, Unit No.002, Building- A, Agastya Corporate Park, Piramal Realty, Kamani Junction, Kurla (W), Mumbai - 400070.

Administrative office address: Axis Securities Limited, Aurum Q Parć, Q2 Building, Unit No. 1001, 10th Floor, Level – 6, Plot No. 4/1 TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai, Pin Code – 400710.

In case of any grievances please call us at 022-40508080 or write to us helpdesk@axisdirect.in.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in last five years. However, SEBI, Exchanges, Clearing Corporations and Depositories etc. have conducted the routine inspection and based on their observations have issued advise/warning/show cause notices/deficiency letters/ or levied penalty or imposed charges for certain deviations observed in inspections or in normal course of business, as a Stock Broker / Depository Participant/Portfolio Manager. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

By referring to any particular sector, Axis Securities does not provide any promise or assurance of favourable view for a particular industry or sector or business group in any manner

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors. Our research should not be considered as an advertisement or advice, professional or otherwise. This research report and its respective content by Axis Securities made available on this page or otherwise do not constitute an offer to sell or purchase or subscribe for any securities or solicitation of any investments or investment services for the residents of Canada and / or USA or any jurisdiction where such an offer or solicitation would be illegal.

Subject company(ies) may have been client during twelve months preceding the date of distribution of the research report. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment of its original date of publication by ASL and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

The information and opinions in this report have been prepared by Axis Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Axis Securities. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite, investment objective or the particular circumstances of an individual investor. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and the like and take professional advice before investing.

While we would endeavour to update the information herein on a reasonable basis, Axis Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Axis Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Axis Securities policies, in circumstances where Axis Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained in good faith from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Axis Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Axis Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Axis Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. Axis Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction. Axis Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months. Axis Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. Axis Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Axis Securities nor Research Analysts and / or their relatives have any material conflict of interest at the time of publication of this report. Please note that Axis Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.



Research Analyst may have served as an officer, director or employee of subject company(ies). Axis Securities or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of Axis Securities and Axis Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report. Axis Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centres on studying charts of a stock'sprice movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Axis Securities may have proprietary long/short position in the above mentioned scrip(s) and therefore may be considered as interested. This should not be construed as invitation or solicitation to do business with Axis Securities. Axis Securities is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independent of the PCG research and accordingly PMS may have positions contrary to the PCG research recommendation.

RATING SCALE: Definitions of ratings

Ratings	Expected absolute returns over 12 – 18 months
BUY	More than 10%
HOLD	Between 10% and -10%
SELL	Less than -10%
NOT RATED	We have forward looking estimates for the stock, but we refrain from assigning valuation and recommendation.
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events
NO STANCE	We do not have any forward-looking estimates, valuation or recommendation for the stock

Note: Returns stated in the rating scale are our internal benchmark.